AMG-0103 is under clinical development by AnGes and currently in Phase I for Chronic Low Back Pain (CLBP). According to GlobalData, Phase I drugs for Chronic Low Back Pain (CLBP) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AMG-0103 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMG-0103 overview
AMG-0103 (NF-kB decoy oligodeoxynucleotide) is under development for the treatment of chronic discogenic lumber back pain. It is administered as an intradiscal injection. It targets NF-kB (nuclear factor-kappa B) which is a transcription factor. It was under development for the treatment of disc degeneration in Japan.
AnGes overview
AnGes is a biopharmaceutical company, which discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. It has two main projects under development, namely, a hepatocyte growth factor (HGF) plasmid, which is a genetic medicine that improves blood circulation by regenerating blood vessels and NF-KB decoy oligonucleotide. It also develops therapeutic vaccine projects including CIN (cervical intraepithelial neoplasia) therapeutic vaccines. The company has operations in the US and Japan. AnGes is headquartered in Ibaraki, Osaka, Japan.
For a complete picture of AMG-0103’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
